A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
A NA clinical study on HIV Infections and Mycobacterium Avium-intracellulare Infection, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Nov 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Nov 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Birmingham, United States, Buffalo, United States, Chicago, United States, Cincinnati, United States, Cleveland, United States, Columbus, United States, Dallas, United States, Galveston, United States, Indianapolis, United States and 10 more location s